Molbio Diagnostics Targets ₹940 Crore in IPO for Global Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an Initial Public Offering (IPO) aimed at raising ₹940 crore. The company intends to allocate ₹200 crore from a fresh issue of shares towards capital expenditures and reduce promoter holdings by generating ₹740 crore through an offer for sale. This strategic move aims to support Molbio's expansion and fortify its position in the global diagnostics market.

Expanding Global Footprint

Founded in 2000, Molbio Diagnostics has steadily established itself as a formidable entity in the diagnostics industry, operating six manufacturing facilities across India. The company serves over 90 countries, providing diagnostic solutions to government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. A significant portion of its revenue, more than 70%, is derived from its tuberculosis diagnostic test kits, highlighting its strong market presence in this domain.

The company's flagship product, the 'Truenat' platform, is a portable diagnostic system that delivers accurate test results within an hour, particularly beneficial for resource-limited settings. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, alongside radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations.

Financial Performance and Market Position

Molbio's financial performance has been robust, with a 31.5% annual increase in revenue from operations, reaching ₹1,445.7 crore between FY24 and FY26. Net profit surged by 40.2% annually to ₹164.1 crore during the same period. The company's EBITDA rose by 33.2% to ₹328.2 crore, with the EBITDA margin improving from 22% in FY24 to 22.6% in FY26. On a year-over-year basis in FY26, revenue grew by 41.7%, EBITDA by 27.9%, and net profit by 18.4%.

With a post-IPO price-earnings (P/E) multiple demand of up to 57, Molbio Diagnostics positions itself competitively among Indian healthcare diagnostics and medical device companies. While it lacks a directly comparable listed peer in India, companies like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre trade at P/E multiples ranging from 54 to 81.

Investor Considerations

The IPO presents an opportunity for high-risk investors to potentially benefit from Molbio's growth trajectory, driven by its innovative diagnostic solutions and global reach. However, investors should be mindful of the company's revenue concentration, with top clients contributing over half of its revenue, and the heavy reliance on government and international aid agencies, which account for over 80% of its revenue.

As Molbio Diagnostics seeks to expand its capabilities and market share, the success of its IPO could significantly bolster its capital structure and drive further innovation in the diagnostics sector.